Antibody-based therapy eliminates circulating tumour cells in mouse models of breast and pancreatic cancer

20 Oct 2022
Antibody-based therapy eliminates circulating tumour cells in mouse models of breast and pancreatic cancer

Investigators have designed an antibody-based treatment that eliminated circulating tumour cells (CTCs) in mouse models of breast and pancreatic cancer.

The research, which was led by scientists at Massachusetts General Hospital (MGH) and is published in PNAS, represents a promising strategy to halt the spread of cancer.

To develop antibody-based therapies that can destroy cancer cells, researchers must identify cell surface proteins that distinguish cancer cells from surrounding normal cells.

In contrast to tumour cells that arise in a particular organ or tissue, CTCs that are spreading, or metastasising, through the blood are in an environment of cells that are much different than they are, which expands the number of targetable proteins for scientists to identify.

Investigators found that cadherins—transmembrane proteins that normally mediate cell–cell adhesion—are great candidates in this case.

An antibody (called 23C6) against cadherins effectively suppressed blood-borne metastasis in mouse models of pancreatic and triple negative breast cancers.

The 23C6 antibody recognises two different cadherins that are commonly expressed on different types of CTCs.

Despite its efficacy against single cells in circulation, the antibody does not suppress the formation of tumours, nor does it elicit detectable toxicity in normal organs, where cadherins may be located within structures connecting cells and hence are inaccessible for antibody binding.

“This therapy may be more effective at targeting CTCs because these antibodies have better access to the circulating cells travelling in the bloodstream and are highly specific to CTCs compared with surrounding blood cells,” says co-author David T Ting, MD, Associate Clinical Director for Innovation at the MGH Cancer Centre and an Associate Professor of Medicine at Harvard Medical School.

The research raises the possibility of developing antibody-based therapies to target CTCs to suppress blood-borne metastasis, which is the predominant cause of cancer mortality.

“While metastasis is the major source of lethality in solid tumours, there are no currently approved therapies that specifically target the metastatic process or the subset of invasive cells responsible for cancer spread,” says Ting.

“The results suggest that our approach could be effective at targeting diverse types of CTCs. With more research and development, therapies that use this approach could be used to prevent cancers from spreading and improve long term survival.”

Article: Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody

Source: Massachusetts General Hospital